ANI introduces generic Lomotil

BAUDETTE, Minn. — ANI Pharmaceuticals on Tuesday announced the introduction of its generic of Lomotil (diphenoxylate HCl and atropine sulfate) tablets. The drug is indicated as an adjunctive therapy to manage diarrhea.

“This is the seventh product that ANI has successfully re-commercialized from its portfolio of acquired discontinued ANDA products,” ANI president and CEO Arthur Przybyl said. “Through the end of the first quarter of 2017, ANI had re-commercialized five of the 54 acquired products. Since the launch of the first product in December 2014 through the end of the first quarter of 2017, these five products have generated cumulative net revenues of $22 million and cumulative gross profit of $12 million to ANI.”

ANI’s generic will be the third generic of Lomotil on the market. The product had a market size of $56 million, according to QuintilesIMS data, the company said.